Ally Stories

Behnke headshot

In today’s dynamic research environment, there is great value in working as a team. At Massachusetts General Hospital Cancer Center, we know that our ability to unlock the most innovative and effective treatments for melanoma relies on the strengths of our partnerships. We’re fortunate that the impact and presence of our collaboration with the Melanoma Research Alliance (MRA) has become deeply embedded in the fabric of our institution.

Since 2008, MRA has generously supported our research efforts through Team Science and Young Investigator Awards. Our top melanoma researchers, including David Fisher, MD, PhD, chief of Dermatology and director of the Melanoma Program as well as the Cutaneous Biology Research Center, and Keith Flaherty, MD, director of the Henri and Belinda Termeer Center for Targeted Therapies, have been welcomed into MRA advisory and review panels to help guide research priorities. MRA-sponsored projects have been co-led by Mass General experts across Dermatology, Hematology/Oncology, and Pathology and have often leveraged the resources and expertise of other top research institutions and academic medical centers.

With a strong alignment in mission and philosophy between our institutions, it was an easy conclusion for us to accept MRA’s invitation to partner together to fund the 2014 Weill Cornell-MGH-MRA Team Science Award. This three-year, $900,000 award, Development of AMPK activators for treatment of melanoma, is now being led by Mass General’s Bin Zheng, PhD, and Lewis Cantley, PhD, of Cornell University. MRA will fund 50 percent of the award with Cornell and Mass General Cancer Center providing matching funds to see the project through to completion.

In my years of experience as a development officer, I’ve rarely seen this type of partnership and approach in the foundation world. By piloting a program that asks funded institutions to provide matching support for their investigators, MRA is able to expand the portfolio of funded research, including the non-traditional, and innovative projects that are unlikely to be funded through more conventional channels. This funding mechanism makes us all equal partners in supporting the research of our top melanoma investigators. The strong relationship and trust between our institutions is what makes this possible. 

Sonja Cropped 2

Sonja Plesset is Vice President for Advancement at Whitehead Institute for Biomedical Research. She has more than 20 years of experience in non-profit management, development, and higher education. At Whitehead Institute, she works closely with faculty and fellows to develop philanthropic relationships with individual, foundation, and corporate donors.

Founded in 1982, Whitehead Institute is a leading, non-profit research institution dedicated to improving human health through basic biomedical research. Whitehead Institute’s 17 faculty members and four fellows run pioneering programs in cancer research, immunology, developmental biology, stem cell research, regenerative medicine, genetics, and genomics.

When I first met with Whitehead Member Piyush Gupta to discuss his melanoma research, I was shocked to learn that while there are targeted drugs for BRAF-mutated melanoma, resistance develops in 100% of patients. Moreover, nearly half of patients have a BRAF mutation.

My first call with Dr. Laura Brockway-Lunardi, MRA’s Scientific Program Director, centered on this sobering fact. We discussed Piyush’s aim to understand how metastatic melanoma resists BRAF-targeted treatments, and his hope to then use this knowledge to improve existing treatments. Laura told us that MRA was interested in translational work as well as high-risk, high-reward research, especially work supported by strong preliminary data. Piyush’s research seemed an excellent fit and a particularly good match for the Young Investigator Award.

After speaking with Laura, I remember Piyush saying that he was struck by how focused MRA is on finding promising research and then seeing how quickly it could be pushed toward the clinic. It “got his attention,” he said.

We then invited MRA to visit and welcomed MRA’s Director of Marketing and Development, Lauren Leiman, to Whitehead Institute over the summer. Lauren met with Piyush and two of his postdocs. Piyush explained that while BRAF-targeting treatments have significantly improved patient outcomes, one-third of patients with the BRAF mutation respond very poorly, and all patients eventually develop resistance to these drugs. He explained that somehow a reservoir of tumor cells “tolerates” these treatments through unknown pathways. Six to eight months after treatment, the resistant cells emerge from this drug-tolerant reservoir and cause relapse.  

Piyush submitted a strong research proposal for the Young Investigator Award, arguing that if he could identify the molecular mechanisms by which cancer cells tolerate BRAF inhibitors then, perhaps, he could use inhibitors of these found pathways in combination with approved BRAF inhibitors to prevent recurrence. This would be a powerful combination product, in his words—a co-inhibitory approach that would reduce tumor growth via known BRAF inhibitors, and then block cancer cells’ resistance to these inhibitors.  

We were delighted when the news arrived that the MRA’s Grant Review Committee rated his proposal favorably and the MRA Board of Directors had decided to support Piyush’s research through the MRA’s collaborative funding vehicle. Because Lauren and I had already developed a strong working relationship, it was easy to imagine how we could utilize our combined networks to locate others who might be interested in helping support Piyush’s pioneering work. Our efforts to recruit co-funders are in the beginning stages, but I am confident that this is the start of a very productive partnership. At the end of the day, our goals are completely aligned—we want to ensure Piyush has the funding he needs to complete his ambitious project that could yield a novel combination therapy which would reduce drug tolerance and improve outcomes in BRAF-mutated melanoma patients. 


Dr. David A. Roth is a Vice President at Pfizer in the Oncology Business Unit.  Dr. Roth leads Pfizer Oncology’s Early Development Group, a global R&D team that develops all Oncology Business Unit pipeline drugs through the Proof-of-Concept development milestone, with a focus on targeted therapies. His portfolio has included palbociclib, a CDK 4/6 cell cycle inhibitor now in phase 3 development for ER+ breast cancer, which is also the focus of a recent MRA-Pfizer partnership award in melanoma.  Prior to entering the biopharmaceutical industry over a decade ago, Dr. Roth was on the full time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center.  His research focused on hemostasis and human gene therapy and he had spent nearly 10 years as a hematologist in academic medicine.

Sometimes, you just get a good feeling about a potential collaboration.  The first time I talked with MRA’s CEO and heard about the organization’s commitment to advancing the most scientifically promising melanoma treatments, we both saw an opportunity to work together to advance cutting-edge melanoma research and, ultimately, help patients.

Less than a week after meeting with one of my colleagues during the 2012 American Society of Clinical Oncology (ASCO) annual conference in Chicago, MRA CEO Wendy Selig sat across from my desk in Cambridge, Massachusetts.  I was struck by her optimism and drive, and we were soon discussing MRA’s Industry Partnership program.  The program is built on stakeholder collaboration; MRA and a biopharma company co-fund a competitively-awarded research grant given to academic investigators in the melanoma field. 

Pfizer has a strong oncology portfolio and world-class R&D resources, but even we cannot independently evaluate every potential treatment across all disease indications and populations.  Palbociclib, a CDK 4/6 inhibitor just given the FDA’s ‘Breakthrough Therapy’ designation for breast cancer, had shown potential in melanoma in the pre-clinical setting, but needed further study.  A partnership built around evaluations of palbociclib in melanoma would enable Pfizer and MRA to bring together their resources and further explore the potential application of this promising investigational agent in melanoma. 

The collaboration fell into place with remarkable speed.  The tone from both Pfizer’s senior leadership and MRA was “How can we make this happen?” and we had our complete agreement and Request For Proposal in place by summer’s end.  The entire process required a high degree of trust on both sides.

Our request for proposals yielded such high-quality applications that MRA came back to us and asked if we would consider funding two projects instead of just one.  MRA’s leadership was excited by the innovative science in the proposals and found additional funds to cover their contribution to the award.  My division secured an internal partner at Pfizer, and we funded the second project as a team. 

Our partnership with MRA stands as an example of what can be accomplished by collaborative medical research: We have the best teams of people working with a sense of urgency on the most innovative science, with everyone’s focus on creating the best possible outcome for melanoma patients.  This type of novel collaboration is a model for the future.



Steve Brody is a partner in the Washington, DC office of the law firm of O’Melveny & Myers LLP, where he is a member of the Class Actions, Mass Torts and Insurance Litigation practice group and head of the practice’s drug and medical device subgroup.  A trial and appellate lawyer, Steve’s practice has frequently touched on policy issues related to the efficient development of new therapies and access to prevention and treatment of cancer and other illnesses.  Steve and O’Melveny have provided pro bono legal representation to the Melanoma Research Alliance (MRA) since 2011, and the firm has also supported MRA through generous financial donations during the same time period.

On November 21, 2009, my friend David “Super Dave” Myers died after a difficult battle with melanoma.  Super Dave (or “Supe,” for short) and I used pack up our guitars and join a group of close friends every Wednesday night for a free-flowing jam session.  Occasionally, we’d even land a slot for a live set at a local bar in DC or the Virginia suburbs. 

We had been getting together for Wednesday night jams for years when Supe was diagnosed with Stage IV melanoma in the Spring of 2009.  He had noticed a spot on one leg some time before then, but delayed seeing a doctor because he had just started a new job and did not have health insurance.  By the time Supe’s leg was examined, it was too late to do much about it. Although Supe's doctors tried aggressive radiation and chemotherapy, his condition deteriorated rapidly. He died the day after his 39th birthday.

My O’Melveny & Myers partner and then firm Chairman A.B. Culvahouse was not aware of my personal connection to melanoma when he introduced me to Wendy Selig, CEO of the Melanoma Research Alliance (MRA), about a year later.  AB only knew that my practice was devoted to litigation that often implicated FDA regulatory questions and that I had previously represented the FDA when I worked for the Department of Justice.  AB correctly thought this experience would lend itself well to exploring opportunities for the firm to provide pro bono legal support to the Melanoma Research Alliance—something that he and Wendy had discussed.  Even without my own exposure to the disease, I would have embraced the opportunity to support MRA.  But having seen the impact the disease had on Supe made it all the more meaningful to find ways to contribute to the organization.  Indeed, everything that MRA does, from promoting melanoma prevention and early detection to funding research into cutting-edge therapies, will help people facing the same diagnosis Supe faced.

From my initial meeting with Wendy, we have been able to identify more and more ways for O’Melveny & Myers to help MRA.  The firm has significant experience in litigation risk assessment, grant agreements, licensing, intellectual property, regulatory approval pathways for new drugs and combination therapies, tax issues, and employment law, among other areas that touch on MRA’s effort to fulfill its mission.  At this stage, nearly three years into our work with MRA, I’m pleased to be able to report that my O’Melveny colleagues across a wide range of practice groups have without exception been willing to share their time and their practice-leading expertise with MRA.  We have reviewed and revised MRA grant agreements, evaluated regulatory impediments to the development of combination therapies, provided guidance for MRA’s tax and employment questions, revised agreements with important MRA partners to protect MRA’s interests, and contributed legal advice on a wide range of other issues confronting MRA.

Over the course of our work, it has been rewarding to see MRA recognized throughout the cancer research, prevention, and advocacy communities.  MRA’s stature has been especially clear to me during MRA’s Annual Scientific Retreats.  Listening to researchers present findings from MRA-sponsored research and speaking with many of those attending, I have been impressed not only by the enthusiasm with which researchers engage each other, but the equal excitement MRA’s Board Members and advocacy group leaders show for MRA’s mission. It is clear that MRA will have a long and successful future, and it is a privilege to be able to contribute to it with our pro bono work.